Seasonal Influenza and Mortality
Can big data from a bad flu season yield insights into all-cause mortality and help guide insurance risk assessment? RGA and Blue Dot partner to explore the global spread of infectious disease and arrive at fascinating insights.
Risk Assessment of the Kidney Transplant Recipient
For underwriters, correctly assessing the potential mortality and morbidity risk of applicants who are past renal transplant recipients involves understanding a broad range of issues related to kidney disease, current transplantation science, long term graft success, post-transplant survival predictors, and the common causes of death in kidney transplant recipients.
Stratifying Mortality Risk Using Physical Activity as Measured by Wearable Sensors
Munich Re assessed the effectiveness of physical activity as measured by wearable sensors in stratifying the mortality risk profile of a U.S. population-based dataset provided by Vivametrica. Munich Re examined the dataset, performed classical actuarial mortality analysis and used survival analysis and machine learning techniques to evaluate the extent to which physical activity predicts mortality.
A Blood Test Can’t Detect Cancer, Can It?
We began 2018 with some promising news on cancer: A simple blood test can now detect disease in eight common sites. Called the CancerSEEK test, it was developed at the Johns Hopkins Kimmel Cancer Center, and may herald a new age in cancer medicine
Look Beyond the Medical Treatments (SCORviews)
If mortality improvement is a three-legged stool, improved treatment of disease is only one leg; the other two legs are prevention and early detection
Underwriting Presentations from M.U.D. 2018
Slides from presentations given at the 48th annual M.U.D. Conference have been posted at their website. Presentations include:
- The Population is Abusing Drugs, but Are Drugs Abusing Insurance?
- Update from the Cuckoo’s Nest: Mental Health Underwriting
- Electronic Medical Records - State of the Union Update
- The Rise and Fall of Liver Biopsy
- Prostate Cancer- To screen or not to screen that is the question
- Through Thick and Thin – Red Blood Cell Disorders
- Hypertrophic Cardiomyopathy: Evaluating Those with a Big Heart
- Using Third Party Scoring in Accelerated Underwriting
- Data Analytics & Underwriting: Are 20th-century regulations still appropriate for 21st-century underwriting?
- Anti Aging, Youthful Medication, Longevity/HGH
- Mind the Gap- Understanding the influence of anti-selection and various holes in the underwriting process of accelerated versus traditional underwriting
Taking Credit (Best's Review)
The predictive power of credit behavior data can accelerate the underwriting process for life insurers.
How ‘Critical’ is Low Risk Prostate Cancer?
Insurers design critical illness policies with the intention being to cover medical conditions that are likely to have a life-changing impact on the life insured, with payment alleviating financial pressure as recovery and adjustment to an altered way of life take place. Should insurers include lower risk prostate cancer in such products or are they well positioned to exclude these altogether, considering the favorable outcome?